Cynata Therapeutics (ASX:CYP)
ASX announcement history & article coverage
Transparent by design.
Announcments by Cynata Therapeutics (ASX:CYP) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notification of cessation of securities - CYP
Final Director's Interest Notice
Board, Management Changes, Expenditure Reductions, RDTI Loan
Cynata Therapeutics cuts all staff including CEO, secures R&D loan, extends cash runway beyond 2027
Ceasing to be a substantial holder
Change in substantial holding
Becoming a substantial holder
Ceasing to be a substantial holder
Investor Webinar
Reinstatement to Official Quotation
Cynata Therapeutics trading suspension lifted after clinical trial results announcements
CYP-004 Osteoarthritis Trial Results
Cynata's Phase 3 CYP-004 Osteoarthritis Trial Shows No Significant Benefit Over Placebo
CYP-001 GvHD Trial Primary Evaluation Results
Cynata Therapeutics terminates Phase 2 CYP-001 trial after no significant efficacy in graft versus host disease
Suspension from Quotation
Cynata Therapeutics requests ASX suspension pending clinical trial results
Trading Halt
EU Positive Opinion on CYP-001 Paediatric Investigation Plan
Cynata secures EMA positive opinion for paediatric trial plan of CYP-001 in aGvHD
WHO Selects Proposed INN for Cymerus MSCs
Expected Timing of Clinical Trial Results
Cleansing Notice
Application for quotation of securities - CYP
Proposed issue of securities - CYP
Cynata Secures Commitments for $1.5m Placement
Cynata Therapeutics Raises A$1.5 Million Placement Ahead of Key Clinical Trial Readouts
March 2026 Quarterly Activity Report & Appendix 4C
Cynata Therapeutics anticipates pivotal trial results in Q2 2026 amid capital raising and sector momentum
Trading Halt